Evidence Level:Sensitive: D – Preclinical
Title:
159 Developing placental CD34+-derived natural killer cells with high affinity cleavage resistant CD16 (CYNK-101) and Cetuximab for enhanced therapy of EGFR+ non-small cell lung and head and neck cancers
Excerpt:Our results demonstrate that CYNK-101 have enhanced Cetuximab-mediated ADCC activity against EGFR+ NSCLC and HNSCC tumor cell lines.
DOI:http://dx.doi.org/10.1136/jitc-2021-SITC2021.159